Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1

Status

Recruiting 2Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 12Breast 4Genitourinary 3Dermatologic 2Tumor-Agnostic 1Thoracic 1Sarcoma 1Other solid neoplasm 1Gynecologic 1CNS 1

Conditions

Breast Neoplasms 3Neoplasm, Residual 1Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer 1

Interventions

Paclitaxel 161Fulvestrant 155Trastuzumab 152pembrolizumab 144Letrozole 136Carboplatin 118pertuzumab 104Cyclophosphamide 102Capecitabine 102Specimen Handling 101Anastrozole 90palbociclib 85abemaciclib 81Magnetic Resonance Spectroscopy 81exemestane 76Docetaxel 76Tamoxifen 75ribociclib 73trastuzumab deruxtecan 69Radiotherapy 61Biopsy 59Surveys and Questionnaires 56Gemcitabine 52130-nm albumin-bound paclitaxel 52sacituzumab govitecan 50olaparib 50Standard of Care 49Blood Specimen Collection 49Taxes 47Doxorubicin 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Hydroxychloroquine × Breast × 1 year × Clear all
NCT04523857 2026-05-26

ABBY

Abramson Cancer Center at Penn Medicine

Phase 2 Recruiting
44 enrolled
Breast

Breast Neoplasms

NCT04841148 2026-04-09

PALAVY

Abramson Cancer Center at Penn Medicine

Phase 2 Recruiting
96 enrolled
Breast

Breast Neoplasms, Neoplasm, Residual

NCT03032406 2025-07-22

CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer

Abramson Cancer Center at Penn Medicine

Phase 2 Active not recruiting
53 enrolled 12 charts
Breast

Breast Neoplasms

NCT07061717 2025-07-11

Comparing Endocrine Therapy Combined With High-Dose Palbociclib and Hydroxychloroquine to Endocrine Therapy Combined With Standard-Dose Palbociclib for Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 3 Not yet recruiting
474 enrolled
Breast

Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡